Xenon to Showcase New Long-Term Azetukalner Data at AES 2024
XENE 11.25.2024
- Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS and findings around mental health and comorbidity burdens of FOS
- New pre-clinical data from the Company’s Nav1.1 program
- Poster Presentation #2.361:Long-term Safety and Efficacy of Azetukalner, a Novel, Potent Kv7 Potassium Channel Opener in Adults With Focal Epilepsy: Update From the Ongoing 7-year Open-Label Extension of X-TOLE
Jacqueline A. French , MD,New York University Grossman School of Medicine and NYU Langone Health Author Session:Sunday, December 8 from12 pm –2 pm PT in South Hall H, Level 1
- Poster Presentation #2.347:Is the Mental Health Burden of Epilepsy Under-Recognized in Patients Reporting Focal Onset Seizures? A Patient-Reported Outcomes StudyAuthor Session:
Sunday, December 8 from12 pm –2 pm PT in South Hall H, Level 1
- Poster Presentation #2.338:A Targeted Literature Review of Comorbidity Burden in Focal Onset SeizuresAuthor Session:
Sunday, December 8 from12 pm –2 pm PT in South Hall H, Level 1
- Poster Presentation #3.389:Nav1.1 Potentiators Modulate Brain Rhythms Measured Through Quantitative Electrocorticography (qECoG) in a Dravet Mouse ModelAuthor Session:
Monday, December 9 from12 pm –2 pm PT in South Hall K, Level 1
- Poster Presentation #3.395:Selective Potentiation of Nav1.1 Channels in Dravet Mice Restores Interneuron Function and Improves Motor FunctionAuthor Session:
Monday, December 9 from12 pm –2 pm PT in South Hall K, Level 1
Scientific Exhibit
Xenon is hosting a Scientific Exhibit to provide an overview of its clinical and research programs on
Exhibit Hall
Xenon is hosting booths #1721 and #1827 in the Exhibit Hall, which is scheduled to open at
About
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical trials; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners’ product candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in our azetukalner and other pipeline and development programs; and our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators’ product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of market, industry, and regulatory conditions on clinical trial enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks identified in our filings with the
“Xenon” and the Xenon logo are registered trademarks or trademarks of
Contacts:For Investors:
For Media:
Source: Xenon Pharmaceuticals Inc.